BD(BDX) Misses Top Line, Stock Down 5% to $81.10
8.6X EBITA Too Rich for LBO Crowd-See Bloomberg article below Becton Dickinson(BDX) announced results for the fiscal first quarter ending Dec 31,2011 with a revenues of $1.842B a decrease of 1.4% from the prior year period.EPS was $1.37(with a tax benefit) compared with $1.25 prior year an 8%...
Healthcare Stocks Lagging the Market in 2011 but Tools and Dx Look Better
Healthcare and Biotechnology stocks are underperforming the S&P YTD-Medical Devices and Equipment are a bright spot up over 4% YTD. The Q4 2010 momentum in biotech stocks has ebbed in 2011 as the broad market rally continues. The S&P is up 5% YTD while the bellwether biotech ETFs IBB...
Bullish Action in Biotech Today
The melt-up resumes. Everyone talks about the really big correction but all we get is a measly 2-3% hit then onward and upward. Metals and materials were ~2% winners today and the NAZ was up 0.75%. Titanium (TIE) was up 7.9 % . What's with that? Although healthcare was up only 0.4% there was...
Rayno Snow Blog: LaNina Mid-Winter Drought
High and Dry in the West Why am I reporting on snow? There is none and little hope for the next seven days-maybe longer. If you like cool sunny dry weather come to SoCal.If you like snow go to NYC or Vancouver BC.I am booking MT for mid-February. Mammoth Lakes Weather brought to you by Howard...
Amgen(AMGN) To Buy Biovex For Cancer Vaccine Technology
Biologics for Treatment of Cancer and Prevention of Infectious Disease Amgen(AMGN) and Biovex said today that both Boards approved the sale of privately held Biovex for $425M with milestone payments as much as $525M. The Biovex lead product OncoVex, an oncolytic vaccine, is in a Phase III...